Navigation Links
ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
Date:1/7/2008

MENLO PARK, Calif., Jan. 7 /PRNewswire/ -- ForSight Labs, LLC announced today the formation and funding of its third company, ForSight VISION3, Inc. with a Series A financing of $6 million, supported by three of the leading venture capital firms in the medical technology arena: Morgenthaler Ventures, Split Rock Partners and Versant Ventures.

"We are excited to have closed a significant round of funding to develop our next innovative ophthalmic technology," said K. Angela Macfarlane, President and CEO of ForSight VISION3. "The ForSight team is already assessing dramatic new opportunities."

The existing ForSight VISION companies, Transcend Medical, and ForSight Newco II (now a wholly owned subsidiary of QLT, Inc.) have each developed high impact products for major ophthalmic markets.

"Ophthalmology continues to have a considerable need for new technologies to address vision loss in all market segments," said Eugene de Juan, Jr. MD, Founder and Vice Chairman of ForSight Labs. "ForSight VISION3 is well positioned to carefully select and develop successful product solutions." Each of the venture partnerships will take a seat on the ForSight VISION3 Board of Directors.

About ForSight Labs, LLC

ForSight Labs is a community of ophthalmic innovation focused on improving the sight, care, and quality of life of visually impaired patients by creating high-impact eye care companies (http://www.forsightlabs.com). ForSight Labs, LLC was established in 2005 by renowned ophthalmologist and retinal surgeon Eugene de Juan, Jr. MD in collaboration with The Foundry (http://www.thefoundry.com). In late 2006, ForSight Labs launched its first company, Transcend Medical, Inc. In October 2007, its second spin out company ForSight Newco II, Inc., developing a proprietary ocular punctal plug drug delivery system, was acquired by QLT Inc. (Nasdaq: QLTI; TSX: QLT). ForSight Labs is backed by investors Morgenthaler Ventures (http://www.morgenthaler.com), Split Rock Partners (http://www.splitrock.com), and Versant Ventures (http://www.versantventures.com).

About Morgenthaler Ventures

Morgenthaler Ventures is a leading, national venture capital team with offices in Menlo Park, CA; Boston, MA; Princeton, NJ, Boulder, CO; and Cleveland, OH. It concentrates its investments in life sciences and information technology.

Morgenthaler's Life Science Team focuses on medical devices and therapeutic pharmaceuticals. Recent investments include Avidia, Morphotek, Threshold Pharmaceuticals, Replidyne, Orexigen, Thermage, Emphasys, Satiety, Cierra, Ardian, Cabochon Aesthetics, Transcend and Xtent. The firm has approximately $2.5 billion under management and has funded more than 250 companies since 1968. For more information on Morgenthaler portfolio companies and the firm, please visit: http://www.morgenthaler.com/ventures.

About Split Rock Partners

Split Rock Partners, with offices in Menlo Park and Minneapolis, invests in emerging opportunities in healthcare and internet services primarily on the West Coast and the Upper Midwest. Split Rock Partners was formed in June, 2004 by the healthcare and software investment teams of St. Paul Venture Capital. In April, 2005, Split Rock announced the closing of a new $275 million venture fund. Split Rock Partners' portfolio of healthcare investments has included such industry leading companies as SpineTech, The Foundry, Dexcom, Emphasys Medical, Xtent, Atritech, Prometheus Labs, and many others. Additional information about the firm can be found at http://www.splitrock.com.

About Versant Ventures

Founded in 1999, Versant Ventures is a leading healthcare venture capital firm that currently manages over $1 billion in committed capital. Since its formation, Versant has invested in more than 75 companies in the Medical Device, Biotech, Healthcare Services and Healthcare Information Technology sectors. The Versant team of twelve investment professionals located in Menlo Park and Newport Beach bring together more than 175 years of combined experience and success as venture capitalists and entrepreneurs. Versant invests in early-stage healthcare companies promising to be significant, long-term market leaders. For additional information, please visit http://www.versantventures.com.


'/>"/>
SOURCE ForSight Labs, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QLT Completes Acquisition of ForSight Newco II, Inc.
2. ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
3. QLT acquires leading edge ocular drug delivery system from ForSight Labs
4. Barc Announces New Travel Size for Its Razor Bump Relief Product
5. Immucor Announces Update to Second Quarter Conference Call Number
6. New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
11. Torchmark Corporation Announces Change in Domicile State of Insurance Subsidiaries to Nebraska
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) continues ... healthcare organizations to promote diabetes education at the World Diabetes Day observance. The ... speakers from around the Commonwealth of Pennsylvania. Speakers included Dr. Renu Joshi ...
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... When faced ... worried about germs spreading from the seat to her body, and contamination of children ... and effective way to solve this problem that many people face. , The patent-pending ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... Cincinnati, Ohio (PRWEB) , ... December 09, 2016 ... ... production of miniature, folded, pharmaceutical inserts and outserts. As a means of ... This addition will enable Flottman to individually code professional inserts (PIs) and ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... share of the market in 2016 and is expected ... be attributed to a large number of surgical procedures ... the largest share in the patient temperature management market.) ... as reducing loss of blood during surgeries, lowering the ...
Breaking Medicine Technology: